Title of thesis: «Study of the pro-apoptotic effect of histones deacetylases inhibitors, used alone and concurrently with chemotherapeutic agents,
on human lung cancer cells».
«Study of the pro-apoptotic effect of molecules interfering with epigenetic mechanisms
on human lung cancer cells».
Not exact matches
One postdoc presents data
on her efforts to develop an organoid model for small -
cell lung cancer; another reports progress
on culturing hormone - secreting organoids from
human gut tissue.
Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small
cell lung cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory
on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta -
human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.
The result was a highly selective drug they named SBI - 0206965, which successfully killed a number of
cancer cell types, including
human and mouse
lung cancer cells and
human brain
cancer cells, some of which were previously shown to be particularly reliant
on cellular recycling.